Agenus (AGEN) 10-Q 9 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 30, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Period Focus	'Q1	'
Document Fiscal Year Focus	'2014	'
Entity Registrant Name	'AGENUS INC	'
Entity Central Index Key	'0001098972	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	62,236,360

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
ASSETS	'	'
Cash and cash equivalents	$73,491,291	$27,351,969
Accounts receivable	0	1,200
Prepaid expenses	1,324,833	658,412
Other current assets	443,798	162,997
Total current assets	75,259,922	28,174,578
Plant and equipment, net of accumulated amortization and depreciation of $27,821,235 and $27,637,443 at March 31, 2014 and December 31, 2013, respectively	4,135,617	2,784,845
Goodwill	19,635,612	2,572,203
Acquired intangible assets, net of accumulated amortization of $73,661 at March 31, 2014	7,997,972	0
Other long-term assets	1,274,646	1,303,855
Total assets	108,303,769	34,835,481
LIABILITIES AND STOCKHOLDERS’ DEFICIT	'	'
Current portion, long-term debt	2,869,301	3,518,550
Convertible notes	1,213,376	0
Current portion, deferred revenue	3,031,744	1,660,679
Accounts payable	1,681,448	834,740
Accrued liabilities	4,699,051	4,215,221
Other current liabilities	878,035	66,683
Total current liabilities	14,372,955	10,295,873
Other long-term debt	5,277,779	5,347,690
Deferred revenue	3,147,754	3,193,809
Contingent royalty obligation	'	18,799,141
Contingent consideration issued in connection with the acquisition of 4-Antibody AG	10,630,000	0
Other long-term liabilities	2,654,627	1,679,671
Commitments and contingencies	'	'
STOCKHOLDERS’ DEFICIT	'	'
Common stock, par value $0.01 per share; 70,000,000 shares authorized; 62,230,609 and 36,391,191 shares issued at March 31, 2014 and December 31, 2013, respectively	622,306	363,912
Additional paid-in capital	711,625,013	644,571,866
Treasury stock, at cost; 0 and 43,490 shares of common stock at March 31, 2014 and December 31, 2013, respectively	0	-324,792
Accumulated deficit	-649,177,681	-649,092,036
Cumulative translation adjustment	215,417	0
Total stockholders’ deficit	63,285,402	-4,480,703
Total liabilities and stockholders’ deficit	108,303,769	34,835,481
Series A-1 convertible preferred stock [Member]	'	'
STOCKHOLDERS’ DEFICIT	'	'
Preferred stock, par value $0.01 per share; 5,000,000 shares authorized at March 31, 2014 and December 31, 2013:	316	316
Series B2 convertible preferred stock	'	'
STOCKHOLDERS’ DEFICIT	'	'
Preferred stock, par value $0.01 per share; 5,000,000 shares authorized at March 31, 2014 and December 31, 2013:	$31	$31

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Feb. 12, 2014	Dec. 31, 2013
Plant and equipment, accumulated amortization and depreciation	$0	'	$27,637,443
Preferred stock, par value	$0.01	'	$0.01
Preferred stock, shares authorized	5,000,000	'	5,000,000
Common stock, par value	$0.01	$0.01	$0.01
Common stock, shares authorized	70,000,000	'	70,000,000
Common stock, shares issued	62,230,609	'	36,391,191
Treasury stock, shares	0	'	43,490
Series A-1 convertible preferred stock, liquidation value	$32,320,630	'	'
Series A convertible preferred stock	'	'	'
Convertible preferred stock, shares designated	'	'	31,620
Preferred stock, shares outstanding Series A-1	0	'	0
Preferred stock, shares issued Series A	0	'	0
Series A-1 convertible preferred stock [Member]	'	'	'
Convertible preferred stock, shares designated	31,620	'	'
Preferred stock, shares outstanding Series A-1	31,620	'	31,620
Preferred stock, shares issued Series A	31,620	'	31,620
Series B2 convertible preferred stock	'	'	'
Convertible preferred stock, shares designated	3,105	'	3,105
Preferred stock, shares outstanding Series A-1	3,105	'	3,105
Preferred stock, shares issued Series A	3,105	'	3,105

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Revenue:	'	'
Service revenue	$0	$725,225
Revenue from Grants	28,768	0
Research and development revenue	692,088	384,017
Total revenues	720,856	1,109,242
Operating expenses:	'	'
Cost of service revenue	0	-272,776
Research and development	-4,472,533	-2,554,122
General and administrative	-5,163,493	-2,891,541
Contingent consideration fair value adjustment	-909,000	0
Operating loss	-9,824,170	-4,609,197
Other income (expense):	'	'
Non-operating income	9,822,466	2,880
Interest expense, net	-355,809	-1,228,702
Net loss	-357,513	-5,835,019
Dividends on Series A and A-1 convertible preferred stock	-51,026	-3,007,186
Net loss attributable to common stockholders	-408,539	-8,842,205
Per common share data:	'	'
Basic and diluted net loss attributable to common stockholders	($0.01)	($0.35)
Weighted average number of common shares outstanding:	'	'
Weighted Average Number of Shares Outstanding, Basic and Diluted 1	50,556,807	25,071,684
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	215,417	0
Other Comprehensive Income (Loss), Net of Tax	215,417	0
Other Comprehensive Income (Loss), Tax	($193,122)	($8,842,205)

Comprehensive_income_loss_Stat

Comprehensive income (loss) Statement (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	$215,417	$0
Other Comprehensive Income (Loss), Net of Tax	215,417	0
Other Comprehensive Income (Loss), Tax	($193,122)	($8,842,205)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net income (loss)	($357,513)	($5,835,019)
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'
Depreciation and amortization	266,528	147,000
Share-based compensation	953,836	709,345
Noncash interest expense	153,146	448,638
Gain on sale of investment	0	0
Loss on disposal of assets	1,150	17,915
Change in fair value of contingent royalty obligation	-8,894,974	0
Loss on extinguishment of debt	0	0
Changes in operating assets and liabilities:	'	'
Accounts receivable	1,200	388,606
Inventories	0	0
Prepaid expenses	-279,825	-341,680
Accounts payable	184,008	-149,686
Deferred revenue	-688,904	-381,971
Accrued liabilities and other current liabilities	-1,433,230	1,026,886
Other operating assets and liabilities	-29,768	74,618
Net cash (used in) provided by operating activities	-10,124,346	-3,895,348
Cash flows from investing activities:	'	'
Cash acquired in acquisition	514,470	0
Purchases of plant and equipment	-172,592	-377,323
Net cash provided by (used in) investing activities	341,878	-377,323
Cash flows from financing activities:	'	'
Net proceeds from sales of equity	56,667,252	0
Proceeds from employee stock purchases	84,271	35,438
Financing of property and equipment	-9,505	-17,078
Payments of convertible notes	-833,333	0
Net cash provided by financing activities	55,908,685	18,360
Effect of exchange rate changes on cash	13,105	0
Net increase in cash and cash equivalents	46,139,322	-4,254,311
Cash and cash equivalents, beginning of period	27,351,969	21,468,269
Cash and cash equivalents, end of period	73,491,291	17,213,958
Supplemental cash flow information:	'	'
Cash paid for interest	-193,893	-3,372
Non-cash investing and financing activity:	'	'
Deemed dividend on Series A convertible preferred stock	0	2,906,664
Issuance of common stock, $0.01 par value, for acquisition of 4-Antibody	10,102,259	0
Contingent consideration issued in connection with the acquisition of 4-Antibody AG	$9,721,000	$0

Description_of_Business

Description of Business	3 Months Ended
	Mar. 31, 2014
Description of Business [Abstract]	'
Business, Liquidity And Basis Of Presentation	'
	Business, Liquidity and Basis of Presentation
	Agenus Inc. including its subsidiaries also referred to as “Agenus,” the “Company,” “we,” “us,” and “our”) is a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators, heat shock protein-based vaccines, and adjuvants. We are focused on immunotherapeutic products based on our core platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners.
	Our core technology portfolio consists of our Retrocyte Display® Technology Platform and Checkpoint Modulator Antibody Programs, our Heat Shock Protein ("HSP")-Based Platform, and our Saponin Adjuvant Platform.
	Our Checkpoint Modulator Antibody Programs became part of our technology portfolio with the acquisition of 4-Antibody AG, a private European-based biopharmaceutical company ("4-AB") in February 2014. This acquisition (see Note C) provides us with a technology platform for the rapid discovery and optimization of fully-human antibodies against a wide array of molecular targets. Within our HSP-Based Platform we are developing our Prophage Series cancer vaccines. Our Prophage Series vaccines are currently being studied in two different settings of glioblastoma multiforme, or GBM: newly diagnosed and recurrent disease. Also within our HSP-Based Platform, is HerpV, a recombinant, synthetic vaccine containing multiple antigens derived from the herpes simplex 2 virus. HerpV is currently in a Phase 2 clinical trial, and we believe it is one of the most clinically-advanced therapeutic vaccines for the treatment of genital herpes in clinical development. Within our Saponin Adjuvant Platform is QS-21 Stimulon® adjuvant, or QS-21 Stimulon, which is used by our licensees in numerous vaccines under development in trials, some as advanced as Phase 3, for a variety of diseases, including cancer, shingles, malaria, Alzheimer's disease, human immunodeficiency virus, and tuberculosis.
	Our business activities have included product research and development, intellectual property prosecution, manufacturing, regulatory and clinical affairs, corporate finance and development activities, and support of our collaborations. Our product candidates require clinical trials and approvals from regulatory agencies, as well as acceptance in the marketplace. In addition to the internal development of our product candidates, we continue to pursue collaborative, out-licensing and/or partnering opportunities for our portfolio programs and product candidates, as well as explore in-licensing, acquisitions and collaborative arrangements in areas of synergy with our existing programs.
	We have incurred significant losses since our inception. As of March 31, 2014, we had an accumulated deficit of $649.2 million. Since our inception, we have financed our operations primarily through the sale of equity, issuance of debt, and interest income earned on cash, cash equivalents, and short-term investment balances. We believe that, based on our current plans and activities, our cash balance of $73.5 million as of March 31, 2014, plus potential proceeds from license, supply, and collaborative agreements will be sufficient to satisfy our liquidity requirements through the first half of 2015. We continue to monitor the likelihood of success of our key initiatives and are prepared to discontinue funding of such activities if they do not prove to be feasible, restrict capital expenditures and/or reduce the scale of our operations.
	We expect to attempt to raise additional funds in advance of depleting our current funds. We may attempt to raise funds by: (1) pursuing collaborative, out-licensing and/or partnering opportunities for our portfolio programs and product candidates with one or more third parties, (2) renegotiating third party agreements, (3) selling assets, (4) securing additional debt financing, and/or (5) selling equity securities. Satisfying long-term liquidity needs may require the successful commercialization and/or substantial out-licensing or partnering arrangements for i) our Retrocyte Display® Technology Platform, Checkpoint Modulator Antibody Programs, HerpV, and the Prophage Series vaccines, ii) vaccines containing QS-21 Stimulon under development by our licensees and/or iii) the identification, development and commercialization of potential other product candidates, each of which will require additional capital with no certainty of timing or probability of success. If we incur operating losses for longer than we expect and/or we are unable to raise additional capital, we may become insolvent and be unable to continue our operations.
	Our research and development program costs include compensation and other direct costs plus an allocation of indirect costs, based on certain assumptions, and our review of the status of each program. Our product candidates are in various stages of research and development and significant additional expenditures will be required if we start new clinical trials, encounter delays in our programs, apply for regulatory approvals, continue development of our technologies, expand our operations, and/or bring our product candidates to market. The eventual total cost of each clinical trial is dependent on a number of factors such as trial design, length of the trial, number of clinical sites, number of patients, and trial sponsorship. The process of obtaining and maintaining regulatory approvals for new therapeutic products is lengthy, expensive, and uncertain. Because our Checkpoint Modulator Antibody Programs are preclinical, HerpV is in a Phase 2 clinical trial, and the further development of our Prophage Series vaccines is subject to evaluation and uncertainty, we are unable to reliably estimate the cost of completing our research and development programs or, the timing for bringing such programs to various markets or substantial partnering or out-licensing arrangements, and, therefore, when, if ever, material cash inflows from operating activities are likely to commence. We will continue to adjust other spending as needed in order to preserve liquidity. Programs involving QS-21 Stimulon, other than our HerpV program, depend on our collaborative partners or licensees successfully completing clinical trials, successfully manufacturing QS-21 Stimulon to meet demand, obtaining regulatory approvals and successfully commercializing product candidates containing QS-21 Stimulon.
	The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete annual consolidated financial statements. In the opinion of our management, the condensed consolidated financial statements include all normal and recurring adjustments considered necessary for a fair presentation of our financial position and operating results. All significant intercompany transactions and accounts have been eliminated in consolidation. Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. For further information, refer to our consolidated financial statements and footnotes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2013 filed with the Securities and Exchange Commission.
	For our subsidiary 4-AB, the local currency is the functional currency. Assets and liabilities of 4-AB are translated into U.S. dollars using rates in effect at the balance sheet date while revenues and expenses are translated into U.S. dollars using average exchange rates. The cumulative translation adjustment resulting from changes in exchange rates are included in the consolidated balance sheets as a component of accumulated other comprehensive income (loss) in total stockholders’ equity.
	The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.

Net_Loss_Income_Per_Share_Note

Net (Loss) Income Per Share (Notes)	3 Months Ended
	Mar. 31, 2014
Net (Loss) Income Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	Net Loss Per Share
	Basic loss and income per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding (including common shares issuable under our Directors’ Deferred Compensation Plan, “DDCP”). Diluted income per common share is calculated by dividing net income attributable to common stockholders by the weighted average number of common shares outstanding (including common shares issuable under our DDCP) plus the dilutive effect of outstanding instruments such as warrants, stock options, nonvested shares, convertible preferred stock, and convertible notes. Because we reported a net loss attributable to common stockholders for all periods presented, diluted loss per common share is the same as basic loss per common share, as the effect of utilizing the fully diluted share count would have reduced the net loss per common share. Therefore, the following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding because they would be anti-dilutive:
		March 31,
		2014	2013
	Warrants	2,951,450	3,309,378
	Stock options	4,267,655	2,830,712
	Nonvested shares	109,747	279,889
	Convertible preferred stock	333,333	333,333
	Convertible notes	382,769	—

4Antibody_Acquisition_Notes

4-Antibody Acquisition (Notes)	3 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Business Combination Disclosure [Text Block]	'
	Note C - 4-Antibody Acquisition
	On January 10, 2014, we entered into a Share Exchange Agreement providing for our acquisition of all of the outstanding capital stock of 4-AB, from the shareholders of 4-AB (the “4-AB Shareholders”). The transaction closed on February 12, 2014 (the "Closing Date"). In exchange for their shares, the 4-AB Shareholders received an aggregate of 3,334,079 shares of our common stock payable upon closing and valued at $10.1 million. Contingent milestone payments of up to $40 million (the "contingent consideration"), payable in cash or shares of our common stock at our option, will be due to the 4-AB Shareholders as follows (i) $20 million upon our market capitalization exceeding $300 million for ten consecutive trading days prior to the earliest of (a) the fifth anniversary of the Closing Date (b) the sale of the 4-AB or (c) the sale of Agenus, (ii) $10 million upon our market capitalization exceeding $750 million for 30 consecutive trading days prior to the earliest of (a) the tenth anniversary of the Closing Date (b) the sale of 4-AB or (c) the sale of Agenus, and (iii) $10 million upon our market capitalization exceeding $1.0 billion for 30 consecutive trading days prior to the earliest of (a) the tenth anniversary of the Closing Date (b) the sale of 4-AB or (c) the sale of Agenus. We have assigned an estimated preliminary fair value of $9.7 million to the contingent consideration. This acquisition provided us with the Retrocyte Display® Technology for the rapid discovery and optimization of fully-human antibodies against a wide array of molecular targets and a portfolio Checkpoint Modulator Antibody immunotherapy program.
	The acquisition of 4-AB was accounted for under the acquisition method of accounting. The purchase price of approximately $19.8 million has been allocated to the tangible and intangible assets acquired and liabilities assumed. The fair value estimate of assets acquired and liabilities assumed is pending completion and final review by our management. Primary areas yet to be finalized include the fair value of certain tangible assets acquired and liabilities assumed, and the valuation of intangible assets acquired. The final purchase price allocation may differ from that presented below due to adjustments that may result from completion of the valuation of the assets acquired and liabilities assumed.
	The following table summarizes the purchase price of the 4-AB acquisition, the identified assets acquired and liabilities assumed at the acquisition date (in thousands):
	Assets acquired:
	Cash		$	514
	Other current assets		600
	Plant and equipment		1,340
	In-process research and development		2,100
	Patented technology		5,700
	Other finite-lived intangible		190
	Goodwill		16,891
	Total assets		27,335
	Liabilities assumed:
	Accounts payable		649
	Other current liabilities		2,889
	Convertible notes		1,142
	Deferred revenue		1,890
	Deferred tax liability		420
	Other long-term liabilities		522
	Total liabilities		7,512
	Total purchase price		$	19,823
	The estimated fair value of the in-process research and development ("IPR&D") and patented technology was determined using the income approach and the relief from royalty rate method, respectively, using significant inputs, including an 18% discount rate, that are not observable.  We consider the fair value of the IPR&D and patented technology to be Level 3 due to the significant estimates and assumptions used by management in establishing the estimated fair values.
	All of the convertible notes assumed in the acquisition were converted into approximately 383,000 shares of our common stock on May 8, 2014.
	The following table summarizes the supplemental statements of operations information on an unaudited pro forma basis as if the 4-AB acquisition had occurred on January 1, 2013 (in thousands except per share data):
		Three months ended March 31,
		2014			2013
	Pro forma revenues	$	926		$	4,858
	Pro forma net loss attributable to common stockholders	$	(1,280	)	$	(7,057	)
	Basic and diluted net loss attributable to common stockholders per share	$	(0.02	)	$	(0.25	)
	The pro forma results presented above are for illustrative purposes only for the periods presented and do not purport to be indicative of the actual results which would have occurred had the transaction been completed as of the beginning of the period, nor are they indicative of results of operations which may occur in the future. Revenues and net loss related to 4-AB of $303,000 and $1.4 million, respectively is included in our condensed consolidated statement of operations and comprehensive income for the quarter ended March 31, 2014.

Goodwill_and_other_intangibles

Goodwill and other intangibles (Notes)	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets Disclosure [Text Block]	'
	Goodwill and Acquired Intangible assets
	The following table sets forth the changes in the carrying amount of goodwill for the three months ended March 31, 2014 (in thousands):
	Balance, December 31, 2013		$	2,572
	Goodwill from 4-AB acquisition		16,891
	Foreign currency translation adjustment		173
	Balance, March 31, 2014		$	19,636
	Acquired intangible assets consisted of the following at March 31, 2014 (in thousands):
		Amortization period (years)		Gross carrying amount		Accumulated amortization			Net carrying amount
	Intellectual Property	15 years		4,850		(40		)	$	4,810
	Trademarks	4.5 years		909		(25		)	$	884
	Other	3 years		192		(9		)	$	183
	In-process research and development	Indefinite		2,121		$	—		$	2,121
	Total			$	8,072	$	(74	)	$	7,998
	The weighted average amortization period of our finite-lived intangible assets is 13 years. Amortization expense related to acquired intangibles is estimated at $442,000 for the balance of 2014, $589,000 for each of the years ending 2015 and 2016, $532,000 for the year ending 2017, $449,000 for the year ending 2018, and $323,000 for each of the years 2019-2028, and $46,000 for the year ending 2029.
	The acquired in-process research and development ("IPR&D") asset relates to the six pre-clinical Checkpoint Modulator Antibody Programs which target GITR, OX40, CTLA-4, PD-1, TIM-3 and LAG-3. IPR&D acquired in a business combination is capitalized at fair value until the underlying project is completed and is subject to impairment testing. Once the project is completed, the carrying value of IPR&D is amortized over the estimated useful life of the asset. Post-acquisition research and development expenses related to the acquired IPR&D are expensed as incurred.

ShareBased_Compensation_Plans_

Share-Based Compensation Plans (Notes)	3 Months Ended
	Mar. 31, 2014
Share-based Compensation [Abstract]	'
Share-Based Compensation	'
	Share-based Compensation Plans
	We use the Black-Scholes option pricing model to value stock options granted to employees and non-employees, as well as stock options granted to members of our Board of Directors. All stock options have 10-year terms and generally vest ratably over a 3 or 4-year period. A non-cash charge to operations for the stock options granted to non-employees that have vesting or other performance criteria is affected each reporting period, until the non-employee options vest, by changes in the fair value of our common stock. A summary of option activity for the three months ended March 31, 2014 is presented below:
		Options		Weighted			Weighted	Aggregate
				Average			Average	Intrinsic
				Exercise			Remaining	Value
				Price			Contractual
							Term
							(in years)
	Outstanding at December 31, 2013	4,163,100		$	5.72
	Granted	175,000		3.27
	Exercised	(12,781	)	3.41
	Forfeited	(43,373	)	3.91
	Expired	(14,291	)	12.83
	Outstanding at March 31, 2014	4,267,655		$	5.62		7.6	$	212,664
	Vested or expected to vest at March 31, 2014	3,684,933		$	6.02		7.3	$	20,291
	Exercisable at March 31, 2014	2,379,328		$	7.07		6.4	$	4,550
	The weighted average grant-date fair values of stock options granted during the three months ended March 31, 2014 and 2013, were $2.54 and $2.88, respectively.
	During the three months ended March 31, 2014, and 2013, all stock options were granted with exercise prices equal to the market value of the underlying shares of common stock on the grant date. As of March 31, 2014, $3.9 million of total unrecognized compensation cost, $556,000 of which pertains to performance awards for which performance has not yet been achieved, related to stock options granted to employees and directors is expected to be recognized over a weighted average period of 2.1 years.
	Certain employees and consultants have been granted nonvested stock. The fair value of nonvested stock is calculated based on the closing sale price of our common stock on the date of issuance.
	A summary of nonvested stock activity for the three months ended March 31, 2014 is presented below:
		Nonvested		Weighted
		Shares		Average
				Grant Date
				Fair Value
	Outstanding at December 31, 2013	147,274		$	3.99
	Granted	—		—
	Vested	(21,319	)	4.65
	Forfeited	(16,208	)	3.4
	Outstanding at March 31, 2014	109,747		3.95
	As of March 31, 2014, there was $264,000 of unrecognized share-based compensation expense related to these nonvested shares awarded to employees expected to be recognized over a weighted average period of 2.5 years. As of March 31, 2014, unrecognized expenses for nonvested shares awarded to outside advisors is $47,000. The total intrinsic value of shares vested during the three months ended March 31, 2014, was $68,000.
	We issue new shares upon stock option exercises, purchases under our 2009 Employee Stock Purchase Plan, vesting of nonvested stock, issuances under the DDCP, and in lieu of approximately 33% of the base salary of our Chief Executive Officer. During the three months ended March 31, 2014, 18,149 shares were issued under the 2009 Employee Stock Purchase Plan, 18,194 shares were issued as a result of the vesting of nonvested stock, 12,781 shares were issued as a result of stock option exercises, and 13,092 shares were issued to our Chief Executive Officer in lieu of cash salary.
	The impact on our results of operations from share-based compensation for the three months ended March 31, 2014, and 2013, was as follows (in thousands):
		Quarter Ended March 31,
		2014			2013
	Research and development	$	254		$	216
	General and administrative	700			493
	Total share-based compensation expense	$	954		$	709

Accrued_Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2014
Other Liabilities Disclosure [Abstract]	'
Other Current Liabilities	'
	Accrued Liabilities
	Accrued liabilities consist of the following as of March 31, 2014 and December 31, 2013 (in thousands):
		31-Mar-14		December 31, 2013
	Professional fees	$	1,627	$	1,121
	Payroll	1,549		1,635
	Clinical trials	826		1,021
	Other	697		438
		$	4,699	$	4,215

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
Fair Value Measurements	'
	Fair Value Measurements
	We measure our contingent royalty obligation and purchase price consideration at fair value. The fair values of our contingent royalty obligation and our purchase price consideration, $8.9 million and $10.6 million, respectively, are based on significant inputs not observable in the market, which require them to be reported as a Level 3 liability within the fair value hierarchy. The valuation uses assumptions we believe would be made by a market participant. In particular, the valuation analysis for the royalty obligation used the Income Approach based on the sum of the economic income that an asset is anticipated to produce in the future. In this case that asset is the potential royalty income to be paid to us as a result of certain license agreements for QS-21 Stimulon and the potential net sales generated from HerpV. The fair value of the contingent royalty obligation is estimated by applying a risk adjusted discount rate (12.5%) to the probability adjusted royalty revenue stream based on expected approval dates. These fair value estimates are most sensitive to changes in the probability of regulatory approvals. The Discounted Cash Flow method of the Income Approach was chosen as the method best suited to valuing the contingent royalty obligation.
	The fair value of our purchase price consideration is based on estimates from Monte Carlo simulation of our market capitalization. Market capitalization was evolved using a geometric brownian motion, calculated daily for the life of the contingent consideration.
	The following table presents our liabilities measured at fair value using significant unobservable inputs (Level 3) , as of March 31, 2014 (amounts in thousands):
	Balance, December 31, 2013	$	18,799
	Contingent purchase price consideration	9,721
	Change in fair value of contingent royalty obligation during the quarter	(9,864		)
	Change in fair value of purchase price consideration during the quarter	909
	Balance, March 31, 2014	$	19,565
	The decrease in fair value of the contingent royalty obligation liability is included in non-operating (loss) income in our condensed consolidated statement of operations for the quarter ended March 31, 2014, and related primarily to the termination by GSK of its Phase 3 clinical trial of a vaccine using our QS-21 Stimulon adjuvant in patients with non-small cell lung cancer. There were no changes in the valuation techniques during the period and there were no transfers into or out of Levels 1 and 2.
	The estimated fair values of all of our financial instruments, excluding long-term debt, approximate their carrying amounts in the condensed consolidated balance sheets. The fair value of our long-term debt was derived by evaluating the nature and terms of each note and considering the prevailing economic and market conditions at the balance sheet date.
	The fair value of our long-term debt at March 31, 2014 and December 31, 2013, was $8.8 million and $9.6 million respectively, based on the Level 2 valuation hierarchy of the fair value measurements standard using a present value methodology. The principal value of our long-term debt at March 31, 2014 and December 31, 2013 was $8.8 million and $9.6 million, respectively.
	In connection with the acquisition of 4-AB, we assumed convertible notes which upon a change of control of 4-AB have the ability to convert into shares of our common stock. We have elected to account for these convertible notes using fair value as a Level 1 liability. Accordingly, the fair value of our convertible notes at March 31, 2014 of $1.2 million, is their carrying value in the condensed consolidated balance sheet.

Equity

Equity	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Equity	'
	Equity
	In February 2014, we issued and sold 22,236,000 shares of our common stock in a public underwritten offering. Net proceeds after deducting offering expenses were approximately $56.0 million. This offering was made under an effective shelf registration statement and proceeds from the offering will be used for general corporate purposes.
	In February 2014, our Board of Directors retired 43,490 shares of our treasury stock then outstanding and returned those shares to authorized and unissued shares of our common stock.
	We issued an aggregate of 3,334,079 shares of our common stock in exchange for all of the outstanding capital stock of 4-AB as detailed in Note C.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In July 2013, the FASB issued Accounting Standards Update No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, ("ASU 2013-11"). ASU 2013-11 amends Accounting Standards Codification 740, Income Taxes, by providing guidance on the financial statement presentation of an unrecognized benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists ("ASC 740"). ASU 2013-11 does not affect the recognition or measurement of uncertain tax positions under ASC 740. ASU 2013-11 will be effective for interim and annual periods beginning after December 15, 2013, with early adoption permitted. The adoption of ASU 2013-11 did not have any impact on our consolidated financial statements.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Subsequent Event
	On April 24, 2014, we amended our certificate of incorporation to increase the authorized number of shares of our common stock from 70,000,000 to 140,000,000 shares.

Net_Loss_Income_Per_Share_Tabl

Net (Loss) Income Per Share (Tables)	3 Months Ended
	Mar. 31, 2014
Net (Loss) Income Per Share [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	Net Loss Per Share
	Basic loss and income per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding (including common shares issuable under our Directors’ Deferred Compensation Plan, “DDCP”). Diluted income per common share is calculated by dividing net income attributable to common stockholders by the weighted average number of common shares outstanding (including common shares issuable under our DDCP) plus the dilutive effect of outstanding instruments such as warrants, stock options, nonvested shares, convertible preferred stock, and convertible notes. Because we reported a net loss attributable to common stockholders for all periods presented, diluted loss per common share is the same as basic loss per common share, as the effect of utilizing the fully diluted share count would have reduced the net loss per common share. Therefore, the following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding because they would be anti-dilutive:
		March 31,
		2014	2013
	Warrants	2,951,450	3,309,378
	Stock options	4,267,655	2,830,712
	Nonvested shares	109,747	279,889
	Convertible preferred stock	333,333	333,333
	Convertible notes	382,769	—

4Antibody_Acquisition_Tables

4-Antibody Acquisition (Tables)	3 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	'
	Assets acquired:
	Cash		$	514
	Other current assets		600
	Plant and equipment		1,340
	In-process research and development		2,100
	Patented technology		5,700
	Other finite-lived intangible		190
	Goodwill		16,891
	Total assets		27,335
	Liabilities assumed:
	Accounts payable		649
	Other current liabilities		2,889
	Convertible notes		1,142
	Deferred revenue		1,890
	Deferred tax liability		420
	Other long-term liabilities		522
	Total liabilities		7,512
	Total purchase price		$	19,823
Business Acquisition, Pro Forma Information [Table Text Block]	'
	The following table summarizes the supplemental statements of operations information on an unaudited pro forma basis as if the 4-AB acquisition had occurred on January 1, 2013 (in thousands except per share data):
		Three months ended March 31,
		2014			2013
	Pro forma revenues	$	926		$	4,858
	Pro forma net loss attributable to common stockholders	$	(1,280	)	$	(7,057	)
	Basic and diluted net loss attributable to common stockholders per share	$	(0.02	)	$	(0.25	)

Goodwill_and_other_intangibles1

Goodwill and other intangibles (Tables)	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Goodwill [Table Text Block]	'
	The following table sets forth the changes in the carrying amount of goodwill for the three months ended March 31, 2014 (in thousands):
	Balance, December 31, 2013		$	2,572
	Goodwill from 4-AB acquisition		16,891
	Foreign currency translation adjustment		173
	Balance, March 31, 2014		$	19,636
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
	Acquired intangible assets consisted of the following at March 31, 2014 (in thousands):
		Amortization period (years)		Gross carrying amount		Accumulated amortization			Net carrying amount
	Intellectual Property	15 years		4,850		(40		)	$	4,810
	Trademarks	4.5 years		909		(25		)	$	884
	Other	3 years		192		(9		)	$	183
	In-process research and development	Indefinite		2,121		$	—		$	2,121
	Total			$	8,072	$	(74	)	$	7,998

ShareBased_Compensation_Plans_1

Share-Based Compensation Plans (Tables)	3 Months Ended
	Mar. 31, 2014
Share-based Compensation [Abstract]	'
Schedule Of Stock Option Activity	'
	A summary of option activity for the three months ended March 31, 2014 is presented below:
		Options		Weighted			Weighted	Aggregate
				Average			Average	Intrinsic
				Exercise			Remaining	Value
				Price			Contractual
							Term
							(in years)
	Outstanding at December 31, 2013	4,163,100		$	5.72
	Granted	175,000		3.27
	Exercised	(12,781	)	3.41
	Forfeited	(43,373	)	3.91
	Expired	(14,291	)	12.83
	Outstanding at March 31, 2014	4,267,655		$	5.62		7.6	$	212,664
	Vested or expected to vest at March 31, 2014	3,684,933		$	6.02		7.3	$	20,291
	Exercisable at March 31, 2014	2,379,328		$	7.07		6.4	$	4,550
Schedule Of Nonvested Shares	'
	A summary of nonvested stock activity for the three months ended March 31, 2014 is presented below:
		Nonvested		Weighted
		Shares		Average
				Grant Date
				Fair Value
	Outstanding at December 31, 2013	147,274		$	3.99
	Granted	—		—
	Vested	(21,319	)	4.65
	Forfeited	(16,208	)	3.4
	Outstanding at March 31, 2014	109,747		3.95
Schedule Of Share-Based Compensation Expense	'
	The impact on our results of operations from share-based compensation for the three months ended March 31, 2014, and 2013, was as follows (in thousands):
		Quarter Ended March 31,
		2014			2013
	Research and development	$	254		$	216
	General and administrative	700			493
	Total share-based compensation expense	$	954		$	709

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2014
Other Liabilities Disclosure [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	Accrued liabilities consist of the following as of March 31, 2014 and December 31, 2013 (in thousands):
		31-Mar-14		December 31, 2013
	Professional fees	$	1,627	$	1,121
	Payroll	1,549		1,635
	Clinical trials	826		1,021
	Other	697		438
		$	4,699	$	4,215

Fair_Value_Measurements_Fair_v

Fair Value Measurements Fair value measurements (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	The following table presents our liabilities measured at fair value using significant unobservable inputs (Level 3) , as of March 31, 2014 (amounts in thousands):
	Balance, December 31, 2013	$	18,799
	Contingent purchase price consideration	9,721
	Change in fair value of contingent royalty obligation during the quarter	(9,864		)
	Change in fair value of purchase price consideration during the quarter	909
	Balance, March 31, 2014	$	19,565

Description_of_Business_Detail

Description of Business (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012
Debt Instruments [Abstract]	'	'	'	'
Accumulated deficit	($649,177,681)	($649,092,036)	'	'
Cash and cash equivalents	$73,491,291	$27,351,969	$17,213,958	$21,468,269

Net_Loss_Income_Per_Share_Anti

Net (Loss) Income Per Share Antidilutive securities (Details)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,951,450	3,309,378
Stock Options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,267,655	2,830,712
Nonvested shares [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	109,747	279,889
Convertible Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	333,333	333,333
Convertible Notes Payable [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	382,769	0

4Antibody_Acquisition_Narrativ

4-Antibody Acquisition (Narrative) (Details) (USD $)	3 Months Ended		0 Months Ended	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	8-May-14	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014
			4-antibody acquisition [Member]	4-antibody acquisition [Member]	Contingent Milestone 1 [Member]	Contingent Milestone 2 [Member]	Contingent Milestone 3 [Member]
					4-antibody acquisition [Member]	4-antibody acquisition [Member]	4-antibody acquisition [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'	'
Fair Value Inputs, Discount Rate	12.50%	'	'	18.00%	'	'	'
Stock Issued During Period, Shares, Acquisitions	'	'	'	3,334,079	'	'	'
Issuance of common stock, $0.01 par value, for acquisition of 4-Antibody	$10,102,259	$0	'	$10,100,000	'	'	'
Contingent Consideration	'	'	'	40,000,000	20,000,000	10,000,000	10,000,000
Market Capitalization	'	'	'	'	300,000,000	750,000,000	1,000,000,000
Consecutive Trading Days	'	'	'	'	'10 days	'30 days	'30 days
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	'	'	'	9,700,000	'	'	'
Business Combination, Consideration Transferred	'	'	'	19,800,000	'	'	'
Revenue	720,856	1,109,242	'	303,000	'	'	'
Net loss	'	'	'	$1,400,000	'	'	'
Debt Conversion, Converted Instrument, Shares Issued	'	'	383,000	'	'	'	'

4Antibody_Acquisition_Purchase

4-Antibody Acquisition (Purchase Price Allocation) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Feb. 12, 2014
			4-antibody acquisition [Member]	4-antibody acquisition [Member]	4-antibody acquisition [Member]
Assets acquired:	'	'	'	'	'
Cash	'	'	'	'	$514,000
Other current assets	'	'	'	'	600,000
Plant and equipment	'	'	'	'	1,340,000
In-Process research and development	'	'	'	'	2,100,000
Patented technology	'	'	'	'	5,700,000
Other finite-lived intangible	'	'	'	'	190,000
Goodwill	19,635,612	2,572,203	'	'	16,891,000
Total assets	'	'	'	'	27,335,000
Liabilities assumed:	'	'	'	'	'
Accounts payable	'	'	'	'	649,000
Other current liabilities	'	'	'	'	2,889,000
Convertible notes	'	'	'	'	1,142,000
Deferred revenue	'	'	'	'	1,890,000
Deferred tax liability	'	'	'	'	420,000
Other long-term liabilities	'	'	'	'	522,000
Total liabilities	'	'	'	'	7,512,000
Total purchase price	'	'	'	'	19,823,000
Business Acquisition, Pro Forma Information [Abstract]	'	'	'	'	'
Pro forma revenue	'	'	926,000	4,858,000	'
Pro forma net loss attributable to common stockholders	'	'	($1,280,000)	($7,057,000)	'
Basic and diluted net loss attributable to common stockholders per share	'	'	$0	$0	'

Goodwill_and_other_intangibles2

Goodwill and other intangibles (Narrative) (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	'13 years
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$442,000
Finite-Lived Intangible Assets, Amortization Expense, Year Four	589,000
Finite-Lived Intangible Assets, Amortization Expense, Year Three	532,000
Finite-Lived Intangible Assets, Amortization Expense, Year Four	449,000
Finite-Lived Intangible Assets, Amortization Expense, Years Five Through Fourteen	323,000
Finite-Lived Intangible Assets, Amortization Expense, Year Fifteen	$46,000

Goodwill_and_other_intangibles3

Goodwill and other intangibles (Schedule of Changes in Goodwill) (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Goodwill [Roll Forward]	'
Beginning balance	$2,572,203
Goodwill from 4-AB acquisition	16,891,000
Foreign currency translation adjustment	173,000
Ending balance	$19,635,612

Goodwill_and_other_intangibles4

Goodwill and other intangibles (Acquired Finite-Lived Intangible Assets) (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Accumulated Amortization	($74,000)	'
Indefinite-lived Intangible Assets Acquired	2,121,000	'
Intangible Assets, Gross (Excluding Goodwill)	8,072,000	'
Intangible Assets, Net (Excluding Goodwill)	7,997,972	0
Intellectual Property [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization period (years)	'15 years	'
Gross carrying amount	4,850,000	'
Accumulated Amortization	-40,000	'
Net carrying amount	4,810,000	'
Trademarks [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization period (years)	'4 years 6 months	'
Gross carrying amount	909,000	'
Accumulated Amortization	-25,000	'
Net carrying amount	884,000	'
Other [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization period (years)	'3 years	'
Gross carrying amount	192,000	'
Accumulated Amortization	-9,000	'
Net carrying amount	$183,000	'

ShareBased_Compensation_Plans_2

Share-Based Compensation Plans (Narrative) (Details) (USD $)

3 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

3 Months Ended

9 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Sep. 30, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Sep. 30, 2013

Sep. 30, 2013

Employees and directors [Member]

Chief Executive Officer [Member]

Outside Advisors [Member]

2009 EIP [Member]

Common Stock [Member]

Performance awards [Member]

Stock Options [Member]

Restricted Stock [Member]

Minimum [Member]

Maximum [Member]

2009 EIP [Member]

2009 EIP [Member]

Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Deferred Compensation Arrangement with Individual, Maximum Contractual Term

'

'

'

'

'

'10

'

'

'

'

'

'

Vesting period, minimum

'

'

'

'

'

'

'

'

'

'

'3 years

'4 years

Weighted average grant-date fair value of options granted

$2.54

$2.88

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized

'

'

$3,900,000

'

$47,000

'

'

$556,000

'

$264,000

'

'

Unrecognized compensation cost, weighted average period

'

'

'

'

'

'

'

'

'2 years 1 month

'2 years 6 months

'

'

Instrinsic value of shares vested

'

'

'

'

'

'

'

'

'

$68,000

'

'

Percentage Of Base Compensation Paid From Stock Compensation Plan

'

'

'

33.00%

'

'

'

'

'

'

'

'

Shares issued under ESPP

'

'

'

'

'

'

18,149

'

'

'

'

'

Shares issued to CEO

'

'

'

13,092

'

'

'

'

'

'

'

'

Shares issued from exercise of options

12,781

'

'

'

'

'

'

'

'

'

'

'

Vesting of nonvested shares, shares

'

'

'

'

'

'

18,194

'

'

'

'

'

ShareBased_Compensation_Plans_3

Share-Based Compensation Plans (Schedule Of Stock Option Activity) (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Share-based Compensation [Abstract]	'
Options outstanding, beginning balance	4,163,100
Options granted	175,000
Options exercised	-12,781
Options forfeited	-43,373
Options expired	-14,291
Options outstanding, ending balance	4,267,655
Options vested or expected to vest	3,684,933
Options exercisable	2,379,328
Options outstanding, weighted average exercise price, beginning balance	$5.72
Options granted, weighted average exercise price	$3.27
Options exercised, weighted average exercise price	$3.41
Options forfeited, weighted average exercise price	$3.91
Options expired, weighted average exercise price	$12.83
Options outstanding, weighted average exercise price, ending balance	$5.62
Options vested or expected to vest, weighted average exercise price	$6.02
Options exercisable, weighted average exercise price	$7.07
Options outstanding, weighted average remaining contractual term	'7 years 7 months 24 days
Options vested or expected to vest, weighted average remaining contractual term	'7 years 3 months
Options exercisable, weighted average remaining contractual term	'6 years 5 months
Options outstanding, aggregate intrinsic value	$212,664
Options vested or expected to vest, aggregate intrinsic value	20,291
Options exercisable, aggregate intrinsic value	$4,550

ShareBased_Compensation_Plans_4

Share-Based Compensation Plans (Summary Of Nonvested Stock Activity) (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Share-based Compensation [Abstract]	'
Nonvested shares outstanding, beginning balance	147,274
Nonvested shares granted	0
Nonvested shares vested	-21,319
Nonvested shares forfeited	-16,208
Nonvested shares outstanding, ending balance	109,747
Nonvested shares outstanding, weighted average grant date fair value, beginning balance	$3.99
Nonvested shares granted, weighted average grant date fair value	$0
Nonvested shares vested, weighted average grant date fair value	$4.65
Nonvested shares forfeited in Period, Weighted Average Grant Date Fair Value	$3.40
Nonvested shares outstanding, weighted average grant date fair value, ending balance	$3.95

ShareBased_Compensation_Plans_5

Share-Based Compensation Plans (Schedule Of Share-Based Compensation Expense) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total share-based compensation expense	$954	$709
Research and Development Expense [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Allocated share-based compensation expense	254	216
General and Administrative Expense [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Allocated share-based compensation expense	$700	$493

Accrued_liabilities_Details

Accrued liabilities (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Accrued liabilitites [Abstract]	'	'
Professional fees	$1,627,000	$1,121,000
Payroll	1,549,000	1,635,000
Clinical trials	826,000	1,021,000
Other	697,000	438,000
Accrued liabilities	$4,699,051	$4,215,221

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014
		Fair Value, Inputs, Level 3 [Member]	Contingent royalty consideration [Member]	Contingent purchase price [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Contingent royalty obligation	$18,799,141	$8,935,252	'	'
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)	'	'	-9,864,000	909,000
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	'	$19,565,000	'	'

Fair_Value_Measurements_Narrat

Fair Value Measurements (Narrative) (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Long-term Debt	$8,800,000	$9,600,000
Contingent Royalty	'	18,799,141
Contingent consideration issued in connection with the acquisition of 4-Antibody AG	10,630,000	0
Fair Value Inputs, Discount Rate	12.50%	'
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Contingent Royalty	8,935,252	'
Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Debt Instrument, Fair Value Disclosure	8,800,000	9,600,000
Convertible Debt	1,200,000	32,100,000
Notes 2006 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Long-term Debt, Gross	'	$37,500,000

Equity_Details

Equity (Details) (USD $)	1 Months Ended	3 Months Ended
In Millions, except Share data, unless otherwise specified	Feb. 20, 2014	Mar. 31, 2014	Mar. 31, 2014
		Underwritten offering [Member]	4-antibody acquisition [Member]
Class of Stock [Line Items]	'	'	'
Stock Issued During Period, Shares, New Issues	'	22,236,000	3,334,079
Proceeds from Issuance of Common Stock	'	$56	'
Treasury Stock, Shares, Retired	43,490	'	'

Subsequent_Events_Details

Subsequent Events (Details)	Mar. 31, 2014	Dec. 31, 2013	Apr. 24, 2014
			Subsequent Event [Member]
Subsequent Event [Line Items]	'	'	'
Common Stock, Shares Authorized	70,000,000	70,000,000	140,000,000